Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
Items 701–800 of 1,000
Treating hypertension in type 2 diabetes
Grossman, Y., Shlomai, G., & Grossman, E. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.947267 · Cited by 11
“, the use of a direct rennin inhibitor, and either an ACEI or an ARB, or the use of an ACEI and an ARB in combination) is not recommended in light of the discouraging results of both the Aliskiren Trial in type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) and the ONTARGET trials [15,42].”
ResultComplete Renin–Angiotensin–Aldosterone System (RAAS) Blockade in High-Risk Patients
Rajagopalan, S., Bakris, G. L., Abraham, W. T., Pitt, B., & Brook, R. D. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01504 · Cited by 9
A possible mechanism for the progression of chronic renal disease and congestive heart failure
Ré, R. N. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.09.016 · Cited by 9
Blood pressure control in CKD—still a matter of debate
Ruilope, L. M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.180 · Cited by 9
Tocci, G., Cicero, A. F. G., Salvetti, M., Musumeci, B., Ferrucci, A., Borghi, C., & Volpe, M. (2017) · Clinical Hypertension · doi:10.1186/s40885-017-0066-0 · Cited by 9
Hirai, T., Yamaga, R., Fujita, A., & Itoh, T. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12720 · Cited by 12
Zuo, Y., Li, T., & Lei, Z. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104286 · Cited by 9
Tang, S. C. W., Chan, K. W., Ip, D., Yap, D. Y. H., Ma, M. K. M., Mok, M. M. Y., Chan, G. C. W., Tam, S., & Lai, K. N. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa085 · Cited by 11
The future of Diabetic Kidney Disease management: reducing the unmet need
de Zeeuw, D. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00820-2 · Cited by 10
Progress in the management of patients with diabetes and chronic kidney disease
Garcia, L. P., Thomas, S. S., Rajesh, H., & Navaneethan, S. D. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000811 · Cited by 10
Complicaciones microvasculares de la diabetes
Pérez‐Pevida, B., Llavero, M., Gargallo, J., & Escalada, J. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.003 · Cited by 15
Uneda, K., Tamura, K., Wakui, H., Azushima, K., Haku, S., Kobayashi, R., Ohki, K., Haruhara, K., Kinguchi, S., Ohsawa, M., et al. (2016) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2016.1200064 · Cited by 11
“Although aliskiren add-on therapy in high-risk type 2 diabetic patients, who had already been treated with ARB or ACE inhibitors, failed to show a benefit for renal and cardiovascular outcomes with an increase in adverse effects in the “Aliskiren Trial in Type 2Diabetes Using Cardiorenal Endpoints” (ALTITUDE) trial (8…”
BackgroundEffect of valsartan on kidney outcomes in people with impaired glucose tolerance
Currie, G. E., Bethel, M. A., Holzhauer, B., Haffner, S. M., Holman, R. R., & McMurray, J. J. V. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12877 · Cited by 11
Self-citationDual renin–angiotensin system blockade for nephroprotection
Ruggenenti, P. L. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.02.006 · Cited by 9
“blockers in 1515 type 2 diabetes patients with overt nephropathy [8].”
BackgroundZaoui, P., Hannedouche, T. P., & Combe, C. (2017) · Néphrologie & Thérapeutique · doi:10.1016/s1769-7255(18)30036-1 · Cited by 9
Patney, V., Chaudhary, K. R., & Whaley‐Connell, A. T. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.11.002 · Cited by 9
Next-generation small molecule therapies for heart failure: 2015 and beyond
Malinowski, J. T., & Jean, D. J. S. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.03.064 · Cited by 9
Ruiz‐García, A., Arranz-Martínez, E., Merchante, I. M., Fuster, V. P., Tamarit, J. J., Trias, F., Pintó, X., & Ascaso, J. F. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.006 · Cited by 14
Marre, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13975 · Cited by 11
“addition to ACE inhibitors or ARBs was tested to prevent CV and adverse renal outcomes in the ALTITUDE study.(57) The study was interrupted as a result of both hyperkalaemia and no observed addi-”
MethodPhillips, J., Chen, J. H. C., Ooi, E. M. M., Prunster, J., & Lim, W. H. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.731574 · Cited by 11
Singh, A. K., & Singh, R. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i7.471 · Cited by 13
Evaluation of Surrogate End Points for Progression to ESKD: Necessary and Challenging
Inker, L. A., & Heerspink, H. J. L. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.08.017 · Cited by 9
Emerging epigenetic modifications in renal fibrosis: From mechanisms to treatments
Suo, X., Ge, Q., Peng, L., Zhu, Q., Zhang, M., Cheng, X., Wang, F., Jin, J., Wang, J., & Meng, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.012 · Cited by 8
“The Alis-kiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints trial was terminated early due to a lack of benefits and increased adverse reactions, including hyperkalemia 13 .”
Chronic kidney disease in older adults: challenges and opportunities for the primary care provider
Brady, B. M., Suffoletto, J.-A., Sankary, R., & Chertow, G. M. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02638-4 · Cited by 10
“While several studies explored the combination of drugs of both classes, there did not appear to be net benefit, and risks, including those of hyperkalemia, hypotension, and abruptly impaired kidney function, were more frequent and/or severe [19– 21].”
BackgroundIshikawa, T., Mori, Niinuma, Nakamura, T., Matsuura, Yokoyama, Utsunomiya, & Aritomi, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s47441 · Cited by 8
Tocci, G., Cicero, A. F. G., Salvetti, M., Francia, P., Ferrucci, A., Borghi, C., & Volpe, M. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2014.115 · Cited by 8
Zhang, L., Mao, Y., Gao, Z., Chen, X., Li, X., Liu, Y., & Xia, G. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00573-9 · Cited by 9
Not all proteinuria is created equal
Beenken, A., Barasch, J. M., & Gharavi, A. G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci133250 · Cited by 8
Management of proteinuria: blockade of the renin-angiotensin-aldosterone system
Athavale, A., & Roberts, D. M. (2020) · Australian Prescriber · doi:10.18773/austprescr.2020.021 · Cited by 9
Säemann, M. D., Cejka, D., Schmaldienst, S., Rosenkranz, A. R., & Mayer, G. J. (2022) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02096-x · Cited by 10
Menezes, A. D. S., Nogueira, T. H. M., de Lima, K. B. A., de Oliveira, H. L., & Botelho, S. M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm15010003 · Cited by 9
“More long-term studies are needed to prove combination therapies’ clinical benefits and cost-effectiveness [57,58].”
Optimizing Care for Canadians with Diabetic Nephropathy in 2015
Lloyd, A., & Komenda, P. V. J. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.11.001 · Cited by 11
LCZ696: The Next Step in Improving RAS Inhibition?
Gradman, A. H. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0548-y · Cited by 9
Update in Hypertension Therapy
Mankin, L. A. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.005 · Cited by 9
Mavrakanas, T. A., & Lipman, M. L. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.006 · Cited by 9
Donderski, R. Ł., Bednarski, R., & Manitius, J. (2020) · Arterial Hypertension · doi:10.5603/ah.a2020.0007 · Cited by 10
“However, the ALTITUDE (The Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) study, comparing the effectiveness of the combination of aliskiren with ACE-I or ARB versus ACE-I or ARB monotherapy in patients with diabetic kidney disease and proteinuria was prematurely terminated due to occurrence of kidney…”
BackgroundManagement of Hyperkalemia in Heart Failure
Altay, H., Çavuşoğlu, Y., Çelik, A., Demir, Ş., Adana Devlet Hastanesi, K. K., Kılıçarslan, B., Tepecik Egitim ve Arastirma Hastanesi, K. K., Nalbantgil, S., Temizhan, A., Tokgöz, B., et al. (2021) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2021.s1 · Cited by 8
“Diyabet hastalarda yapılmış olan ALTITUDE (The Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) ve VA NEPHRON-D (Veterans Affairs Nephropathy in Diabetes) çalışmalarında[19,20] hiperkalemi (K+ >6 mEq/L), kombine RAASi kullanan grupta anlamlı derecede daha sık görülmüştür (ALTITUDE’de %11.”
EASD, E. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0289 · Cited by 13
Management of Diabetic Nephropathy in Older Patients: A Need for Flexible Guidelines
Abdelhafiz, A. H., Nahas, M. E., & Oliveira, J. M. F. D. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.07.2794 · Cited by 9
Prevention of Coronary Artery Disease: Recent Advances in the Management of Hypertension
Recarti, C., & Unger, T. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0311-2 · Cited by 9
Do patients with chronic kidney disease get optimal cardiovascular risk reduction?
Elliott, M. K., McCaughan, J. A., & Fogarty, D. G. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000444913.78536.b1 · Cited by 10
“Higher rates of hyperkalaemia, hypotension and deterioration in renal function were observed in patients treated with the direct renin antagonist, which may explain the poorer cardiovascular outcome in this group [51].”
BackgroundRastogi, A., Arman, F., & Alipourfetrati, S. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0663-4 · Cited by 8
Clinical Trials in Autosomal Dominant Polycystic Kidney Disease
Yu, A. S. L., Ters, M. E., & Winklhofer, F. T. (2015) · Codon Publications eBooks · doi:10.15586/codon.pkd.2015.ch6 · Cited by 10
Elrggal, M. E., Ahmed, S. M. S., & Nahas, M. E. (2016) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.194583 · Cited by 8
Blood pressure management in patients with type 2 diabetes mellitus
Kai, H. (2017) · Hypertension Research · doi:10.1038/hr.2017.55 · Cited by 8
Havakuk, O., & Elkayam, U. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416683049 · Cited by 11
Personalized medicine in diabetic kidney disease
Idzerda, N. M. A., Pena, M. J., & Heerspink, H. J. L. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000447 · Cited by 8
Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach
Bonino, B., Leoncini, G., Cosmo, S. D., Greco, E., Russo, G. T., Giandalia, A., Viazzi, F. C., & Pontremoli, R. (2019) · Medicina · doi:10.3390/medicina55070382 · Cited by 8
Therapeutic Renin Inhibition in Diabetic Nephropathy—A Review of the Physiological Evidence
Massolini, B. D., Contieri, S. S. G., Lazarini, G. S., Bellacosa, P. A., Dobre, M. A., Petroianu, G. A., Brateanu, A., Campos, L. A., & Baltatu, O. C. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00190 · Cited by 8
“As such, important information that could lead to patient stratification could be learned from disclosing the PRA data from the ALTITUDE study (Parving et al., 2012).”
BackgroundMethodInfluentialSuehiro, T., Tsuruya, K., Yoshida, H., Tsujikawa, H., Yamada, S., Tanaka, S., Tsuchimoto, A., Eriguchi, M., Fujisaki, K., Torisu, K., et al. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000512365 · Cited by 8
Bhattacharyya, A., Gallo, P. P., Crisp, A., LaVange, L. M., Molenberghs, G., Pétavy, F., & Seltzer, J. H. (2018) · Biometrical Journal · doi:10.1002/bimj.201700307 · Cited by 9
“In the case of another outcomes trial, an excess risk of adverse reactions led to termination of the ALTITUDE study in the use of the renin inhibitor aliskiren in Type 2 diabetics with chronic kidney and/or chronic cardiovascular disease (Parving et al., 2012).”
BackgroundRenin Inhibition in Heart Failure and Diabetes: The Real Story
Rosano, G. M. C., Seferovic, P. M., Farmakis, D. T., & Filippatos, G. S. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1072 · Cited by 8
Fravel, M. A., Meaney, C. J., & Noureddine, L. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01265-1 · Cited by 9
Weldon, S. M., Cogan, D. A., Cerny, M. A., Frederick, K. S., Gueneva-Boucheva, K., Clifford, H. E., Kugler, S. Z., Marshall, D. R., Richman, J. G., & Brown, N. F. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103649 · Cited by 9
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Barrios, V., & Escobar, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.834887 · Cited by 7
Brunström, M., & Carlberg, B. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001663 · Cited by 8
Reddin, C., Murphy, R., Hanrahan, C., Loughlin, E. A., Ferguson, J. P., Judge, C. S., Waters, R., Canavan, M. D., Kenny, R. A., & O'Donnell, M. J. (2023) · Age and Ageing · doi:10.1093/ageing/afad044 · Cited by 8
“Eight trials ( n = 59,603) reported orthostatic hypotension, and there were 2,071 orthostatic hypotension events during the follow-up [ 19–22, 24, 31, 38, 41].”
BackgroundQian, F., Zhao, L., Zhang, D., Yu, M., Zhou, W. J., & Jin, J. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13683 · Cited by 7
Ueno, M., Fujii, W., Ono, W., Murata, H., Fujigaki, Y., & Shibata, S. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad099 · Cited by 8
Vitamin D: A Bridge between Kidney and Heart
Secondulfo, C., Visco, V., Virtuoso, N., Fortunato, M., Migliarino, S., Rispoli, A., Mura, L. L., Stellato, A., Caliendo, G., Settembre, E., et al. (2024) · Life · doi:10.3390/life14050617 · Cited by 10
“Since the acknowledgement of potential serious adverse effects of “dual blockade” of RAAS, combined with the lack of evidence of a reduction in mortality and improvement of kidney function of this therapeutic regimen, there has been a need for drugs capable of limiting residual proteinuria [86–88].”
BackgroundYu, D., Li, J., Cheng, Y., Wang, H., Ma, X., Ding, T., & Zhu, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313309 · Cited by 9
Renin inhibitors versus angiotensin receptor blockers for primary hypertension
Wang, G. M., Li, L. J., Fan, L., Xu, M., Tang, W. L., & Wright, J. M. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012570.pub2 · Cited by 12
El-Haddad, B. N., Reule, S. A., & Drawz, P. E. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0640-3 · Cited by 7
Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku
Suplement, K. P. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0177 · Cited by 18
Al-Hajji, A., Alsubaie, H. A., Albaqshi, H. T., Al-Hajji, H., AlEssa, F. A., & Ali, B. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_244_20 · Cited by 7
“Though, the clinical outcome of urinary albumin‐to‐creatinine ratio levels in addition to the estimated glomerular filtration rate on outcomes in diabetic nephropathy needs to be identified.[9]”
BackgroundHypertension Management in Patients with Chronic Kidney Disease in the Post-SPRINT Era
Jung, H. H. (2021) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2021.19.2.19 · Cited by 8
Waijer, S. W., Provenzano, M., Mulder, S., Rossing, P. R., Persson, F., Perkovic, V., & Heerspink, H. J. L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14660 · Cited by 8
“The study design and principal results of the ALTITUDE trial have been published elsewhere.(12,13) For our analysis we selected participants at the first study visit (pre-screening), who were randomly assigned to placebo treatment.”
MethodSelf-citationRastogi, A., & Weir, M. R. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108515 · Cited by 8
Schievink, B., Mol, P. G. M., & Heerspink, H. J. L. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000159 · Cited by 8
Non-interventional management of resistant hypertension
Doumas, M. N., Tsioufis, C., Faselis, C., Lazaridis, A., Grassos, H., & Papademetriou, V. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i10.1080 · Cited by 7
Pharmacologic Treatment of Hypertension in Patients With Chronic Kidney Disease
Talreja, H., Ruzicka, M., & McCormick, B. B. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0009-4 · Cited by 14
“Similarly, the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) trial was halted prematurely as preliminary data demonstrated a slight increase in cardiovascular events (death or stroke), and increased risk of renal impairment, hypotension, and hyperkalemia in a group of patients taking alisk…”
ResultNew renal drug development to face chronic renal disease
Moll, S., Meier, M., Formentini, I., Pomposiello, S. I., & Prunotto, M. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.956075 · Cited by 7
“Indeed, despite the retrospective learning from the RENAAL and INDT trials [94], recent failed studies [95,96] have shown limitations of this biomarker for pivotal clinical trials for drug approval [92].”
Fox, C. H., Neuhaus, K., & Vassalotti, J. (2013) · OA Nephrology · doi:10.13172/2053-0293-1-3-1027 · Cited by 10
Ito, S., Kagawa, T., Saiki, T., Shimizu, K., Kuroda, S., Sano, Y., & Umeda, Y. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07720618 · Cited by 7
Tereshchenko, S. N., Arutyunov, G. P., Galyavich, A. S., Ильинична, Г. Н., Gilyarevsky, S. R., Duplyakov, D. V., Жиров, И. В., Скибицкий, В. В., Ткачева, О. Н., & Иосифович, Ш. И. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-2-3748 · Cited by 7
Renna, N. F., Piskorz, D. L., Stisman, D., Martínez, D., Lescano, L., Vissani, S., Espeche, W. G., Márquez, D. F., Parodi, R., Naninni, D., et al. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00557-w · Cited by 8
Dual renin–angiotensin system blockade and outcome benefits in hypertension: a narrative review
Mann, J. F. E., & Böhm, M. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000173 · Cited by 7
Awdishu, L., Moore, T., Morrison, M., Turner, C., & Trzebinska, D. (2019) · Pharmacy · doi:10.3390/pharmacy7030083 · Cited by 9
(2020) · Diabetes : current and future developments · doi:10.2174/97898114220031200101 · Cited by 7
Slowing Progression of Chronic Kidney Disease
Drawz, P. E., Hostetter, T. H., & Rosenberg, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00057-7 · Cited by 10
Staying up to date with the JNC 8 hypertension guideline
Feldman, H. A., Zuber, K., & Davis, J. S. (2014) · JAAPA · doi:10.1097/01.jaa.0000451865.17954.9b · Cited by 8
Diabetes, aliskiren, and heart failure: let's bring ASTRONAUT down to earth
Cleland, J. G. F., Clark, A., Costanzo, P., & Francis, D. P. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht366 · Cited by 7
“investigated the effects of aliskiren in 8561 patients with type 2 diabetes (T2DM) and chronic kidney or cardiovascular disease.(6) The”
BackgroundZhao, K., Tang, H., Zhu, H., & Zhang, W. (2024) · IEEE Access · doi:10.1109/access.2024.3372188 · Cited by 6
“Table 6 presents the predicted results alongside the corresponding evidence from previous studies [58], [59], [60], [61], [62].”
ResultDual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease
Feng, Y., & Fu, P. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.172599 · Cited by 9
“The Aliskiren Trial in Type 2 Diabetes Using Cardio‑renal Endpoints study investigated whether the use of aliskiren would reduce cardiovascular and renal events among patients with type 2 diabetes and CKD.[62] A total of 8561 patients were randomly assigned to the aliskiren (300 mg/d) or placebo group, in addition to…”
BackgroundNassif, M. E., & Kosiborod, M. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.003 · Cited by 6
Risk of stroke in patients with diabetic retinopathy: A systematic review and meta-analysis
Gong, L., Liu, Y., Lian, H., Lei, R., Ren, M., Wang, X., & Wang, Y. (2023) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2023.08.025 · Cited by 6
Forouzanmehr, B., Hedayati, A. H., Gholami, E., Hemmati, M. A., Maleki, M., Butler, A. E., Jamialahmadi, T., Kesharwani, P., Yaribeygi, H., & Sahebkar, A. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111335 · Cited by 8
Parvan, R., Aboumsallem, J. P., Meijers, W. C., de Boer, R. A., & Danser, A. H. J. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177110 · Cited by 7
Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpoint
Little, D. J., Jongs, N., BRINKER, M. D., Gasparyan, S. B., Schloemer, P., & Heerspink, H. J. L. (2025) · Kidney International · doi:10.1016/j.kint.2025.03.011 · Cited by 6
Hypertension management in patients with advanced chronic kidney disease with and without dialysis
Suarez, M. L. G., Arriola‐Montenegro, J., & Rolón, L. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001221 · Cited by 6
Jugdutt, B. I. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0268-2_18 · Cited by 6
Cardiorenal Syndromes: Advances in Determining Diagnosis, Prognosis and Therapy
McCullough, P. A., & Tumlin, J. A. (2015) · Journal of Cardiovascular Diseases & Diagnosis · doi:10.4172/2329-9517.1000221 · Cited by 6
Optimal targets for blood pressure control in chronic kidney disease: the debate continues
Knight, J. F., Wong, M. G., & Perkovic, V. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000060 · Cited by 6
Tani, S., Kushiro, T., Takahashi, A., Kawamata, H., Ohkubo, K., Nagao, K., & Hirayama, A. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.5629 · Cited by 6
Translational science in albuminuria: a new view ofde novoalbuminuria under chronic RAS suppression
Martin, M. B., Rodríguez‐Sánchez, E., Gonzalez‐Calero, L., Ruilope, L. M., Álvarez‐Llamas, G., Barderas, M. G., & Ruiz‐Hurtado, G. (2018) · Clinical Science · doi:10.1042/cs20180097 · Cited by 6
Veitch, M. R., Thai, K., Zhang, Y., Desjardins, J., Kabir, G., Connelly, K. A., & Gilbert, R. E. (2020) · Nephrology · doi:10.1111/nep.13828 · Cited by 6
Bhagwati, S., & Siddiqi, M. I. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1860825 · Cited by 6
“However, aliskiren has also been shown to have severe adverse effects in patients with diabetes, kidney, and heart diseases (Parving et al., 2012).”
BackgroundResultJiang, Y., Li, Z., Yue, R., Liu, G., Yang, M., Long, C., & Yan, D. (2023) · Food & Function · doi:10.1039/d3fo02407e · Cited by 7
Direct renin inhibition: extricating facts from façades
Juncos, L. A. (2013) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944713479995 · Cited by 6
Hyperuricemia Predicts Kidney Disease Progression After Acute Allograft Dysfunction
Weng, S., Shu, K.-H., Wu, M., Cheng, C.-H., Chen, C., Yu, T., Chuang, Y., Huang, S., & Tarng, D. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.09.040 · Cited by 6
“We investigated the role of hyperuricemia in the composite doubling of serum creatinine and graft failure by using survival analysis [20,21].”
Method
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.